Nathan Congdon, MD, highlights a recent study showing how virtual mentor-mentee relationships through Orbis' free ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

The risk of systemic side effects is greater in infants than in adults due to increased percutaneous drug absorption and lower blood volume. The closed eyes technique of eyedrop administration is ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Feb. 11, 2025 — A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau. This is the finding of new research which also offers a better way ...

The Western Australian preterm birth prevention initiative: a whole of state singleton pregnancy cohort study showing the need to embrace alternative models of care for Aboriginal women.